We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Commentary on Abstract #1718

  • Bruce D. Cheson, MD
Mar 1, 1999
Volume: 
13
Issue: 
3
  • Oncology Journal

Campath-1H is an anti-CD52 monoclonal antibody that has demonstrated impressive activity in patients with relapsed chronic lymphocytic leukemia (CLL) and in those with T-cell prolymphocytic leukemia (T-PLL). Initial clinical trials with this agent were terminated early because of excessive toxicity, ie, myelosuppression and infections. Nevertheless, the investigators were impressed by the activity of the antibody in patients with advanced CLL.

A less intensive schedule was developed and has now been used in a series of protocols. Österborg et al (J Clin Oncol 15:1567-1574, 1997) first described 29 patients with refractory or relapsed CLL with a response rate of 42%, including a 4% rate of complete remissions. Pawson et al (J Clin Oncol 15:2667-2672, 1997) reported on 15 patients with T-PLL, many of whom had already not responded to a purine analog. These patients had a 60% complete remission rate, with an overall response rate of 73%.

Österborg et al (abstract #1718) now report their results with 50 patients with advanced low-grade NHL treated with Campath-1H. The response rate was surprisingly low at 20%, including two (4%) complete remissions. Although lymphoma cells were rapidly cleared from the blood in 94% of patients, a complete response in the bone marrow was induced in only 32%, and lymph nodes returned to normal size in only 5%.

The failure to resolve lymphadenopathy is similar to what has been observed with rituximab. The explanation for this finding is unknown and may reflect an inability of the antibody to penetrate into the node. Lymphopenia was pronounced in the study of Österborg et al, with seven patients experiencing an opportunistic infection, and nine cases of septicemia. Future studies should evaluate the use of prophylactic antimicrobial agents to reduce the morbidity associated with Campath-1H , and alternate schedules of administration should be explored to minimize toxicity while maintaining efficacy.

Related Articles

  • Implications of Mutation Profiling in Myeloid Malignancies—PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia
  • Systemic Treatment Options for Brain Metastases from Non–Small-Cell Lung Cancer
  • Secondary Prevention Strategies for Nonmelanoma Skin Cancer
  • Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune Disease
  • Bilateral, Multifocal Renal Masses in a 35-Year-Old Man With a History of Tuberous Sclerosis Complex

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.